

Title of Trial: A Phase IV, prospective, open label multicentre study of Raptiva 1mg/kg/week by subcutaneous injection in adults with moderate to severe chronic plaque psoriasis who have failed previous biologic therapy with etanercept.

Investigational Product: Efalizumab

Trial No.: EMR700515-501

Study Centers: Not available

Trial Initiation Date: 26 September 2008

Trial Completion Date: 11 April 2009

Development Phase: Phase 4

Publication (reference): None

Study Objectives: Data not available

Methodology: Data not available

Number of Subjects (Planned and Analyzed): Data not available

Diagnosis and Main Criteria for Inclusion/Exclusion: Data not available

Study Treatment: Data not available

Criteria for Evaluation: Data not available

Statistical Methods: Data not available

Results: Data not available

Conclusions: Data not available

Due diligence was done and all potential information sources have been exhausted. No source documents for this study were identified. Due to non-availability of clinical study reports and synopses, results were not posted in EudraCT database

Merck KGaA

These results are supplied for informational purposes only.